Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung disease or congenital heart disease) at high risk of severe and potentially lethal course of the infection. This drug was reported to be safe, well tolerated and effective to decrease the hospitalization rate and mortality in these groups of infants by several clinical trials. In the present paper we report the development and the current use of monoclonal antibodies for prophylaxis against respiratory syncytial virus.
Marcello Lanari, Silvia Vandini, Santo Arcuri, Silvia Galletti, Giacomo Faldella (2013). The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013, 1-9 [10.1155/2013/359683].
The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
VANDINI, SILVIA;ARCURI, SANTO;GALLETTI, SILVIA;FALDELLA, GIACOMO
2013
Abstract
Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung disease or congenital heart disease) at high risk of severe and potentially lethal course of the infection. This drug was reported to be safe, well tolerated and effective to decrease the hospitalization rate and mortality in these groups of infants by several clinical trials. In the present paper we report the development and the current use of monoclonal antibodies for prophylaxis against respiratory syncytial virus.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
